MAIA
AMEXMAIA Biotechnology Inc.
Price$1.09-0.03 (-2.68%)
03:30 PM07:45 PM
News · 26 weeks56+67%
2026-04-192026-10-11
Mix2890d
- Insider11(39%)
- SEC Filings8(29%)
- Other8(29%)
- Offering1(4%)
Latest news
25 items- PRMAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerEnrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI) in the ongoing Phase 2 and pivotal Phase 3 clinical trials of its novel telomere-targeting agent ateganosine as a treatment for non-small cell lung cancer (NSCLC). Enrollment is complete for the Part C of
- SECSEC Form 424B3 filed by MAIA Biotechnology Inc.424B3 - MAIA Biotechnology, Inc. (0001878313) (Filer)
- SECSEC Form EFFECT filed by MAIA Biotechnology Inc.EFFECT - MAIA Biotechnology, Inc. (0001878313) (Filer)
- SECSEC Form 8-K filed by MAIA Biotechnology Inc.8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
- INSIDERSEC Form 4 filed by Director Theagene Jean-Manasse4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Stan4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- INSIDERSEC Form 4 filed by Director Luput Cristian4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- INSIDERSEC Form 4 filed by Director Louie Ngar Yee4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- INSIDERSEC Form 4 filed by Director Guerrero Ramiro4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- SECSEC Form 424B3 filed by MAIA Biotechnology Inc.424B3 - MAIA Biotechnology, Inc. (0001878313) (Filer)
- INSIDERSEC Form 4 filed by Director Chaouki Steven M4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- PRDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)New York, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology’s business, recent updates, management commentary, financial results, and risks. The full update note is available below. MAIA Biotechnology October 2026 Update Note Strong Phase 3 THIO-104 Enrollment Momentum Supports Visibility Toward Key 2027 Overall Survival Readout: With enro
- SECSEC Form S-3 filed by MAIA Biotechnology Inc.S-3 - MAIA Biotechnology, Inc. (0001878313) (Filer)
- PRMAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and PortugalTHIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for its ongoing pivotal Phase 3 THIO-104 clinical trial in non-small cell lung cancer (NSCLC). Spain and Portugal represent important European markets for NSCLC, with an estimated 30,000 new cases annually acro
- PRMAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung CancerStrong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLC CHICAGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that enrollment has reached 65 patients in its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC).
- PRMAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical TrialMilestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-small cell lung cancer (NSCLC). The U.S. Phas
- PRMAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEOCHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10, 2026, at an average common stock price of $1.36. MAIA also announced that 73,000 shares of MAIA common stock were acquired by Founder and CEO Vlad Vitoc, M.D. on September 14, 2026, at an average common sto
- INSIDERChief Executive Officer Vitoc Vlad bought $100,010 worth of shares (73,000 units at $1.37), increasing direct ownership by 7% to 1,049,121 units (SEC Form 4)4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- INSIDERDirector Guerrero Ramiro bought $49,516 worth of shares (37,595 units at $1.32), increasing direct ownership by 5% to 773,296 units (SEC Form 4)4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- PRMAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced its presentation of a poster featuring its second-generation telomere-targeting anticancer drug candidates at the recent XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026) held in Barcelona, Spain. MAIA's lead drug candidate, ateganosine, is a first-in-class telomere-targeting therapy designed to selectively damage cancer-cell telom
- INSIDERDirector Guerrero Ramiro bought $184,103 worth of shares (133,790 units at $1.38), increasing direct ownership by 22% to 735,701 units (SEC Form 4)4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- SECSEC Form EFFECT filed by MAIA Biotechnology Inc.EFFECT - MAIA Biotechnology, Inc. (0001878313) (Filer)
- INSIDERDirector Guerrero Ramiro bought $2,386 worth of shares (1,794 units at $1.33), increasing direct ownership by 0.30% to 601,911 units (SEC Form 4)4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- INSIDERDirector Guerrero Ramiro bought $16,302 worth of shares (11,899 units at $1.37), increasing direct ownership by 2% to 600,117 units (SEC Form 4)4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
- SECSEC Form S-3 filed by MAIA Biotechnology Inc.S-3 - MAIA Biotechnology, Inc. (0001878313) (Filer)
MAIA FAQ
5 questionsWhere does MAIA stock trade?
MAIA Biotechnology Inc. (MAIA) is listed on AMEX.What sector and industry is MAIA in?
MAIA Biotechnology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MAIA Biotechnology Inc. go public?
MAIA Biotechnology Inc. (MAIA) completed its IPO in 2022.What companies are similar to MAIA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MAIA side-by-side with any of them on Quantisnow.How can I track MAIA on Quantisnow?
Quantisnow aggregates MAIA Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MAIA to receive live email and push alerts on every new disclosure.